Skip to main content
NCBI home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2014 Sep 28;30(5):823–837. doi: 10.1007/s12264-014-1472-x

Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson’s disease

Shichun Peng 1, David Eidelberg 1, Yilong Ma 1,✉
PMCID: PMC4556355  NIHMSID: NIHMS718582  PMID: 25260798

Abstract

Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made significant strides in describing the pathophysiology of Parkinson’s disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, we review the relevant clinical applications in patients in relation to healthy volunteers with a focus on the generation of unique spatial covariance patterns associated with the motor and cognitive symptoms underlying PD. These characteristic biomarkers can be potentially used not only to improve patient recruitment but also to predict outcomes in clinical trials.

Keywords: Parkinson’s disease, metabolism, blood flow, PET, SPECT, movement disorder, network analysis, imaging biomarkers

References

  • [1].Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1–16. doi: 10.1016/j.neuroimage.2004.04.039. [DOI] [PubMed] [Google Scholar]
  • [2].Peng S, Doudet DJ, Dhawan V, Ma Y. Dopamine PET imaging and Parkinson’s disease. PET Clin. 2013;8:469–485. doi: 10.1016/j.cpet.2013.08.003. [DOI] [PubMed] [Google Scholar]
  • [3].Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain function in Parkinson’s disease: truth or fiction? Neuroimage. 2009;45:260–266. doi: 10.1016/j.neuroimage.2008.09.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].Catalan MJ, Ishii K, Honda M, Samii A, Hallett M. A PET study of sequential finger movements of varying length in patients with Parkinson’s disease. Brain. 1999;122:483–495. doi: 10.1093/brain/122.3.483. [DOI] [PubMed] [Google Scholar]
  • [5].Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson’s disease. Adv. Neurol. 2003;91:9–18. [PubMed] [Google Scholar]
  • [6].Braak H, Del Tredici K. Cortico-basal ganglia-cortical circuitry in Parkinson’s disease reconsidered. Exp Neurol. 2008;212:226–229. doi: 10.1016/j.expneurol.2008.04.001. [DOI] [PubMed] [Google Scholar]
  • [7].Brownell AL, Canales K, Chen YI, Jenkins BG, Owen C, Livni E, et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson’s disease model. Neuroimage. 2003;20:1064–1075. doi: 10.1016/S1053-8119(03)00348-3. [DOI] [PubMed] [Google Scholar]
  • [8].Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 2005;22:283–287. doi: 10.1111/j.1460-9568.2005.04196.x. [DOI] [PubMed] [Google Scholar]
  • [9].Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain. 2001;124:1601–1609. doi: 10.1093/brain/124.8.1601. [DOI] [PubMed] [Google Scholar]
  • [10].Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912–921. doi: 10.1016/j.neuroimage.2005.03.012. [DOI] [PubMed] [Google Scholar]
  • [11].Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395–2404. doi: 10.1002/mds.23291. [DOI] [PubMed] [Google Scholar]
  • [12].Powers WJ, Videen TO, Markham J, Black KJ, Golchin N, Perlmutter JS. Cerebral mitochondrial metabolism in early Parkinson’s disease. J Cereb Blood Flow Metab. 2008;28:1754–1760. doi: 10.1038/jcbfm.2008.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, et al. Monosymptomatic resting tremor and Parkinson’s disease: a multitracer positron emission tomographic study. Mov Disord. 2002;17:782–788. doi: 10.1002/mds.10125. [DOI] [PubMed] [Google Scholar]
  • [14].Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease. J Cereb Blood Flow Metab. 2004;24:7–16. doi: 10.1097/01.WCB.0000092831.44769.09. [DOI] [PubMed] [Google Scholar]
  • [15].Lozza C, Marie RM, Baron JC. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson’s disease. Neuroimage. 2002;17:688–699. doi: 10.1006/nimg.2002.1245. [DOI] [PubMed] [Google Scholar]
  • [16].Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. Neuroimage. 2006;31:301–307. doi: 10.1016/j.neuroimage.2005.12.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia. Neurology. 1999;52:541–546. doi: 10.1212/WNL.52.3.541. [DOI] [PubMed] [Google Scholar]
  • [18].Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord. 2009;24:854–862. doi: 10.1002/mds.22444. [DOI] [PubMed] [Google Scholar]
  • [19].Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:537–544. doi: 10.1007/s00259-009-1259-x. [DOI] [PubMed] [Google Scholar]
  • [20].Arahata Y, Hirayama M, Ieda T, Koike Y, Kato T, Tadokoro M, et al. Parieto-occipital glucose hypometabolism in Parkinson’s disease with autonomic failure. J Neurol Sci. 1999;163:119–126. doi: 10.1016/S0022-510X(99)00011-8. [DOI] [PubMed] [Google Scholar]
  • [21].Wu JC, Iacono R, Ayman M, Salmon E, Lin SD, Carlson J, et al. Correlation of intellectual impairment in Parkinson’s disease with FDG PET scan. Neuroreport. 2000;11:2139–2144. doi: 10.1097/00001756-200007140-00016. [DOI] [PubMed] [Google Scholar]
  • [22].Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson’s disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord. 2009;24:1504–1511. doi: 10.1002/mds.22662. [DOI] [PubMed] [Google Scholar]
  • [23].Boecker H, Ceballos-Baumann A, Bartenstein P, Weindl A, Siebner HR, Fassbender T, et al. Sensory processing in Parkinson’s and Huntington’s disease: investigations with 3D H(2)(15)O-PET. Brain. 1999;122:1651–1665. doi: 10.1093/brain/122.9.1651. [DOI] [PubMed] [Google Scholar]
  • [24].Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, et al. Functional correlates of pallidal stimulation for Parkinson’s disease. Ann Neurol. 2001;49:155–164. doi: 10.1002/1531-8249(20010201)49:2<155::AID-ANA35>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • [25].Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson’s disease. J Nucl Med. 1999;40:1583–1589. [PubMed] [Google Scholar]
  • [26].Kikuchi A, Takeda A, Kimpara T, Nakagawa M, Kawashima R, Sugiura M, et al. Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson’s disease. J Neurol Sci. 2001;193:29–36. doi: 10.1016/S0022-510X(01)00641-4. [DOI] [PubMed] [Google Scholar]
  • [27].Abe Y, Kachi T, Kato T, Arahata Y, Yamada T, Washimi Y, et al. Occipital hypoperfusion in Parkinson’s disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry. 2003;74:419–422. doi: 10.1136/jnnp.74.4.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, et al. Heterogeneous factors in dementia with Parkinson’s disease: IMP-SPECT study. Parkinsonism Relat Disord. 2007;13:174–181. doi: 10.1016/j.parkreldis.2006.10.005. [DOI] [PubMed] [Google Scholar]
  • [29].Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O’Brien JT. Regional cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage. 2003;20:1309–1319. doi: 10.1016/S1053-8119(03)00364-1. [DOI] [PubMed] [Google Scholar]
  • [30].Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson’s disease with and without dementia. Mov Disord. 2005;20:999–1005. doi: 10.1002/mds.20463. [DOI] [PubMed] [Google Scholar]
  • [31].Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson’s disease: methodological issues. Neuroimage. 2011;54:2899–2914. doi: 10.1016/j.neuroimage.2010.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385–398. doi: 10.1097/00004647-199605000-00005. [DOI] [PubMed] [Google Scholar]
  • [33].Hsu JL, Jung TP, Hsu CY, Hsu WC, Chen YK, Duann JR, et al. Regional CBF changes in Parkinson’s disease: a correlation with motor dysfunction. Eur J Nucl Med Mol Imaging. 2007;34:1458–1466. doi: 10.1007/s00259-006-0360-7. [DOI] [PubMed] [Google Scholar]
  • [34].Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry. 2002;159:746–754. doi: 10.1176/appi.ajp.159.5.746. [DOI] [PubMed] [Google Scholar]
  • [35].Chen K, Reiman EM, Huan Z, Caselli RJ, Bandy D, Ayutyanont N, et al. Linking functional and structural brain images with multivariate network analyses: a novel application of the partial least square method. Neuroimage. 2009;47:602–610. doi: 10.1016/j.neuroimage.2009.04.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage. 1996;4:223–235. doi: 10.1006/nimg.1996.0074. [DOI] [PubMed] [Google Scholar]
  • [37].McIntosh AR, Bookstein FL, Haxby JV, Grady CL. Spatial pattern analysis of functional brain images using partial least squares. Neuroimage. 1996;3:143–157. doi: 10.1006/nimg.1996.0016. [DOI] [PubMed] [Google Scholar]
  • [38].Carbon M, Eidelberg D. Function al imaging of sequence learning in Parkinson’s disease. J Neurol Sci. 2006;248:72–77. doi: 10.1016/j.jns.2006.05.005. [DOI] [PubMed] [Google Scholar]
  • [39].Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007;27:597–605. doi: 10.1038/sj.jcbfm.9600358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Niethammer M, Eidelberg D. Ann Neurol. 2012. Metabo lic brain networks in translational neurology: Concepts and Applications. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Kaasinen V, Maguire RP, Hundemer HP, Leenders KL. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson’s disease. J Neurol. 2006;253:340–348. doi: 10.1007/s00415-005-0993-7. [DOI] [PubMed] [Google Scholar]
  • [42].Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson’s disease. Brain. 2007;130:1834–1846. doi: 10.1093/brain/awm086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. Reproducibility of Regional Metabolic Covariance Patterns: Comparison of Four Populations. Journal of Nuclear Medicine. 1999;40:1264–1269. [PubMed] [Google Scholar]
  • [44].Wu P, Wang J, Peng S, Ma Y, Zhang H, Guan Y, et al. Metabolic brain network in the Chinese patients with Parkinson’s disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord. 2013;19:622–627. doi: 10.1016/j.parkreldis.2013.02.013. [DOI] [PubMed] [Google Scholar]
  • [45].Teune LK, Renken RJ, Mudali D, De Jong BM, Dierckx RA, Roerdink JB, et al. Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord. 2013;28:547–551. doi: 10.1002/mds.25361. [DOI] [PubMed] [Google Scholar]
  • [46].Ma Y, Peng S, Spetsieris PG, Sossi V, Eidelberg D, Doudet DJ. Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab. 2012;32:633–642. doi: 10.1038/jcbfm.2011.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47].Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23:727–733. doi: 10.1002/mds.21933. [DOI] [PubMed] [Google Scholar]
  • [48].Poston KL, Tang CC, Eckert T, Dhawan V, Frucht S, Vonsattel JP, et al. Network correlates of disease severity in multiple system atrophy. Neurology. 2012;78:1237–1244. doi: 10.1212/WNL.0b013e318250d7fd. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y, et al. Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage. 2011;54:1244–1253. doi: 10.1016/j.neuroimage.2010.09.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34:714–723. doi: 10.1016/j.neuroimage.2006.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [51].Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp. 2004;22:236–245. doi: 10.1002/hbm.20033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, et al. Metabolic correlates of pallidal neuronal activity in Parkinson’s disease. Brain. 1997;120:1315–1324. doi: 10.1093/brain/120.8.1315. [DOI] [PubMed] [Google Scholar]
  • [53].Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease. Brain. 2008;131:1373–1380. doi: 10.1093/brain/awn031. [DOI] [PubMed] [Google Scholar]
  • [54].Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord. 2002;17:1265–1270. doi: 10.1002/mds.10270. [DOI] [PubMed] [Google Scholar]
  • [55].Eckert T, Van Laere K, Tang C, Lewis DE, Edwards C, Santens P, et al. Quantification of Parkinson’s disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging. 2007;34:496–501. doi: 10.1007/s00259-006-0261-9. [DOI] [PubMed] [Google Scholar]
  • [56].Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson’s disease and Huntington’s disease. Mol Imaging Biol. 2007;9:223–233. doi: 10.1007/s11307-007-0085-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [57].Ma Y, Huang C, Dyke JP, Pan H, Alsop D, Feigin A, et al. Parkinson’s disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab. 2010;30:505–509. doi: 10.1038/jcbfm.2009.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [58].Melzer TR, Watts R, MacAskill MR, Pearson JF, Rueger S, Pitcher TL, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain. 2011;134:845–855. doi: 10.1093/brain/awq377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [59].Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology. 2001;57:2083–2088. doi: 10.1212/WNL.57.11.2083. [DOI] [PubMed] [Google Scholar]
  • [60].Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, Sturm V, et al. Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson’s disease: measuring the on- and off-conditions with FDG-PET. J Neural Transm. 2002;109:1257–1264. doi: 10.1007/s00702-002-0696-5. [DOI] [PubMed] [Google Scholar]
  • [61].Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci. 2008;28:4201–4209. doi: 10.1523/JNEUROSCI.0582-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England journal of medicine. 2003;349:1925–1934. doi: 10.1056/NEJMoa035275. [DOI] [PubMed] [Google Scholar]
  • [63].Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362:2077–2091. doi: 10.1056/NEJMoa0907083. [DOI] [PubMed] [Google Scholar]
  • [64].Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol. 2012;11:429–442. doi: 10.1016/S1474-4422(12)70049-2. [DOI] [PubMed] [Google Scholar]
  • [65].Payoux P, Remy P, Miloudi M, Houeto JL, Stadler C, Bejjani BP, et al. Contrasting changes in cortical activation induced by acute high-frequency stimulation within the globus pallidus in Parkinson’s disease. J Cereb Blood Flow Metab. 2009;29:235–243. doi: 10.1038/jcbfm.2008.107. [DOI] [PubMed] [Google Scholar]
  • [66].Fukuda M, Barnes A, Simon ES, Holmes A, Dhawan V, Giladi N, et al. Thalamic stimulation for parkinsonian tremor: correlation between regional cerebral blood flow and physiological tremor characteristics. Neuroimage. 2004;21:608–615. doi: 10.1016/j.neuroimage.2003.09.068. [DOI] [PubMed] [Google Scholar]
  • [67].Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. Network modulation in the treatment of Parkinson’s disease. Brain. 2006;129:2667–2678. doi: 10.1093/brain/awl162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Trost M, Su PC, Barnes A, Su SL, Yen RF, Tseng HM, et al. Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg. 2003;99:872–878. doi: 10.3171/jns.2003.99.5.0872. [DOI] [PubMed] [Google Scholar]
  • [69].Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of me tabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease. J Neurol. 2010;257:72–78. doi: 10.1007/s00415-009-5267-3. [DOI] [PubMed] [Google Scholar]
  • [70].Karimi M, Golchin N, Tabbal SD, Hershey T, Videen TO, Wu J, et al. Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain. 2008;131:2710–2719. doi: 10.1093/brain/awn179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [71].Geday J, Ostergaard K, Johnsen E, Gjedde A. STN-stimulation in Parkinson’s disease restores striatal inhibition of thalamocortical projection. Hum Brain Mapp. 2009;30:112–121. doi: 10.1002/hbm.20486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [72].Sestini S, Ramat S, Formiconi AR, Ammannati F, Sorbi S, Pupi A. Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson’s disease: a 4-year follow-up study with rCBF SPECT. J Nucl Med. 2005;46:1444–1454. [PubMed] [Google Scholar]
  • [73].Limousin P, Greene J, Pollak P, Rothwell J, Benabid AL, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson’s disease. Ann Neurol. 1997;42:283–291. doi: 10.1002/ana.410420303. [DOI] [PubMed] [Google Scholar]
  • [74].Thobois S, Hotton GR, Pinto S, Wilkinson L, Limousin-Dowsey P, Brooks DJ, et al. STN stimulation alters pallidal-frontal coupling during response selection under competition. J Cereb Blood Flow Metab. 2007;27:1173–1184. doi: 10.1038/sj.jcbfm.9600425. [DOI] [PubMed] [Google Scholar]
  • [75].Ballanger B, Lozano AM, Moro E, van Eimeren T, Hamani C, Chen R, et al. Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson’s disease: A [(15)O] H(2)O PET study. Hum Brain Mapp. 2009;30:3901–3909. doi: 10.1002/hbm.20815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [76].Alessandro S, Ceravolo R, Brusa L, Pierantozzi M, Costa A, Galati S, et al. Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J Neurol Sci. 2010;289:44–48. doi: 10.1016/j.jns.2009.08.017. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES